XRF Scientific Limited (XRF) AI Stock Analysis

• Market Cap: AU$219.24M
• Dividend Yield: 2.44%
• Average Volume (3M): 238.96K
• Price to Earnings (P/E): 23.0
• Beta (1Y): 1.14
• Revenue Growth: 6.00%
• EPS Growth: 10.26%
• Country: AU
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 68
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.04
• Shares Outstanding: 140,536,070
• 10 Day Avg. Volume: 141,430
• 30 Day Avg. Volume: 238,962
• PEG Ratio: 4.48
• Price to Book (P/B): 3.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 23.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.22
• Price Target Upside: 42.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: AU$2.00 ▲(28.21%Upside)

XRF Scientific Limited's overall stock score is bolstered by strong financial performance, characterized by robust profit margins and low leverage, which indicate a stable financial position. However, technical analysis shows mixed signals, and the high P/E ratio suggests the stock may be overvalued, which partially offsets the positive financial metrics.

XRF Scientific Limited Business Overview & Revenue Model

Company Description

XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries in Australia, Canada, and Europe. It operates through Capital Equipment, Precious Metals, and Consumables segments. The Capital Equipment segment designs, manufactures, and services automated fusion equipment, and high temperature test and production furnaces, as well as general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. The company was founded in 1972 and is based in Osborne Park, Australia.

How the Company Makes Money

XRF Scientific Limited generates revenue through the sale of its advanced equipment and consumables to laboratories and facilities involved in material analysis and testing. Key revenue streams include the sale of fusion equipment, which is used for preparing samples for X-ray fluorescence (XRF) and inductively coupled plasma (ICP) analysis, and the sale of associated consumables like fluxes and crucibles. The company also earns from providing technical support and maintenance services for its equipment. Significant partnerships with mining companies and research institutions contribute to a steady demand for its products, driving consistent revenue growth.

XRF Scientific Limited Financial Statement Overview

Summary

XRF Scientific Limited demonstrates strong financial performance with robust revenue growth, high profit margins, and low leverage. The company maintains financial stability and operational efficiency, though attention is needed on cash flow trends to ensure sustained liquidity.

Income Statement

XRF Scientific Limited has shown a strong revenue growth rate of 8.45% from 2023 to 2024, with significant gross profit and net profit margins at 43.88% and 14.85% respectively for 2024. The company also maintains a robust EBIT margin of 24.15% and an EBITDA margin of 25.61%, indicating solid operational efficiency. However, monitoring future revenue growth is crucial to maintain this trajectory.

Balance Sheet

The company exhibits financial stability with a low debt-to-equity ratio of 0.06, reflecting conservative leverage. A healthy return on equity (ROE) of 16.19% suggests effective use of shareholders' funds. An equity ratio of 80.43% underscores strong financial independence, minimizing risk of solvency issues. Nonetheless, maintaining such low leverage might limit growth potential.

Cash Flow

XRF Scientific Limited experienced a decrease in operating cash flow to net income ratio from 2023 to 2024, but maintains a positive free cash flow to net income ratio of 0.73, indicating sufficient cash generation. However, the free cash flow growth rate declined by 15.56%, warranting attention to reverse this trend for sustained liquidity and investment capacity.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
60.08M	59.84M	55.17M	40.01M	31.29M	29.08M
	Gross Profit
27.43M	26.27M	22.00M	16.46M	12.89M	11.34M
	EBIT
15.23M	14.45M	12.76M	8.79M	6.38M	4.84M
	EBITDA
15.97M	15.32M	13.22M	9.44M	8.05M	5.86M
	Net Income Common Stockholders
9.42M	8.89M	7.69M	6.08M	5.13M	3.12M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.13M	12.05M	10.40M	6.65M	5.26M	3.63M
	Total Assets
66.27M	68.23M	65.55M	55.56M	48.37M	45.17M
	Total Debt
4.57M	3.38M	4.31M	3.51M	1.44M	1.94M
	Net Debt
-3.56M	-8.67M	-6.09M	-3.14M	-3.82M	-1.70M
	Total Liabilities
12.07M	12.69M	15.97M	12.21M	9.27M	9.53M
	Stockholders Equity
54.21M	54.89M	49.25M	43.48M	39.10M	35.64M
Cash Flow		Free Cash Flow
9.37M	6.45M	7.63M	2.63M	3.86M	3.45M
	Operating Cash Flow
10.37M	8.09M	8.42M	3.15M	4.51M	4.20M
	Investing Cash Flow
-2.03M	-1.64M	-782.43K	-1.11M	-652.62K	-753.41K
	Financing Cash Flow
-8.53M	-4.80M	-3.88M	-648.95K	-2.24M	-3.05M

XRF Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.62, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.28 is Neutral, neither overbought nor oversold. The STOCH value of 34.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:XRF.

XRF Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XRF	70 Outperform	AU$219.24M	23.04	18.04%	2.44%	6.00%	10.26%
Sector *	51 Neutral	$2.04B	-1.15	-21.24%	3.95%	2.91%	-30.44%
BRCHF		$306.23M	―	-133.28%	―	―	―
CMXHF		$76.87B	28.01	15.38%	1.73%	―	―
RMD	79 Outperform	AU$57.06B	28.38	25.23%	1.31%	10.54%	38.69%
BTH	55 Neutral	$176.66M	―	-33.75%	―	-11.19%	-174.51%
ALC	54 Neutral	AU$123.55M	―	-5.63%	―	-11.96%	7.50%

XRF Scientific Limited Corporate Events

XRF Scientific Director Increases Shareholding

XRF Scientific Limited announced a change in the director’s interest, with Vance Stazzonelli acquiring 10,000 ordinary shares, increasing his total to 850,000 shares. This change, executed through a combination of off-market and on-market trades, reflects ongoing adjustments in the company’s leadership investments, potentially impacting stakeholder perceptions and the company’s market dynamics.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Reports Mixed Results in March 2025 Quarter

XRF Scientific Limited reported a mixed performance in its March 2025 quarterly trading report, with a 9% decrease in revenue to $13.9 million compared to the previous year, but a 5% increase in profit before tax to $3.4 million. The company continues to see growth potential in international markets, driven by the mining industry and international sales, particularly in Asia, the Americas, and Europe. Despite global trade tensions, XRF remains focused on expanding its international sales and exploring new product developments and M&A opportunities.

XRF Scientific Limited Announces Director’s Interest Change

XRF Scientific Limited has announced a change in the director’s interest notice, specifically regarding David Brown’s indirect interest in the company’s securities. On March 13 and 14, 2025, Brown acquired 32,000 ordinary shares through an on-market trade, increasing his indirect holdings to 3,466,128 shares. This transaction, valued at $56,960, reflects ongoing adjustments in the company’s leadership investment strategies, potentially impacting stakeholder perceptions and the company’s market positioning.

XRF Scientific Limited Announces Quotation of New Securities

XRF Scientific Limited announced the quotation of 42,886 ordinary fully paid securities on the ASX, issued under an employee incentive scheme. This move may enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.